Strong second quarter for Synthes despite effects of downturn
This article was originally published in Clinica
Orthopaedic specialist Synthes reported a strong second quarter. This was despite ongoing negative economic conditions and pricing pressures in North America and Europe, as well as government-sanctioned price reductions in Japan. The Solothurn, Switzerland-based company recorded sales of around $892.2m for the period, a 7% improvement on the same quarter last year. Second-quarter revenue was up in North America (+4% to $531.4m), Europe (+3% to $195.3m), Asia-Pacific (+22% to $101.6m) and the rest of the world (+39% to $63.9m). In Q1, the firm displayed equally as solid figures with total sales growing by 13% to $911.7m (www.clinica.co.uk, 29 April 2010).
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals